SPY305.92+0.37 0.12%
DIA256.43+1.16 0.45%
IXIC9,505.22-46.83 -0.49%

Myovant Sciences Reports Will Present New Data On Relugolix In Prostate Cancer At ASCO May 29

Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will present new efficacy and cardiovascular safety data from the Phase 3 HERO study

Benzinga · 05/14/2020 12:37

Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will present new efficacy and cardiovascular safety data from the Phase 3 HERO study of once-daily, oral relugolix (120 mg) in men with advanced prostate cancer at the American Society of Clinical Oncology (ASCO)’s upcoming ASCO20 Virtual Scientific Program, to be held May 29-31, 2020.  

The new data will be presented by Neal Shore, M.D., medical director of the Carolina Urologic Research Center and HERO program steering committee member. Dr. Shore’s presentation (#5602), titled “HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer” will be included in the oral abstract session, “Genitourinary Cancer—Prostate, Testicular, and Penile,” which will be available for on-demand viewing starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time on Friday, May 29, 2020.

In April 2020, Myovant submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for relugolix as a potential treatment for men with advanced prostate cancer. The NDA is supported by positive results from the Phase 3 HERO study, a randomized pivotal study comparing relugolix versus leuprolide acetate.